Priority 12 from the Mesothelioma PSP

UNCERTAINTY: How can the levels of mesothelin (a protein present in mesothelioma cells that can be measured in the blood) best be incorporated in the diagnosis, response and progression of mesothelioma? (JLA PSP Priority 12)
Overall ranking 12
JLA question ID 0025/12 
Explanatory note Not available for this PSP
Evidence Systematic review - Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ Open. 2014 Feb 24;4(2):e004145. doi: 10.1136/bmjopen-2013-004145
Health Research Classification System category Cancer
Extra information provided by this PSP
Original uncertainty examples Five years ago my blood was analysed by an immunologist who discovered immunity to mesothelin and 5T4, two antigens which express with mesothelioma
Comparison Diagnostics
Submitted by Patient
Outcomes to be measured Diagnosis
PSP information
PSP unique ID 0025
PSP name Mesothelioma
Total number of uncertainties identified by this PSP. 53  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop 16 December 2014